Findings of Research Misconduct, 47589-47590 [2011-19930]

Download as PDF Federal Register / Vol. 76, No. 151 / Friday, August 5, 2011 / Notices format and alternative media, including large print/type; digital disk; and audio and video tape. Best Copy and Printing, Inc. may be reached by e-mail at FCC@BCPIWEB.com. Federal Communications Commission. Bulah P. Wheeler, Deputy Manager, Office of the Secretary, Office of Managing Director. [FR Doc. 2011–20006 Filed 8–3–11; 4:15 pm] BILLING CODE 6712–01–P FEDERAL ELECTION COMMISSION Sunshine Act Notice AGENCY: Federal Election Commission. FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 76 FR 45798 (August 1, 2011). Thursday, August 4, 2011, at 10 a.m. PLACE: 999 E Street, NW., Washington, DC (Ninth Floor). STATUS: Meeting open to the public. CHANGES IN THE MEETING: The following item was withdrawn from the agenda: Proposed Final Audit Report on John Edwards for President. Individuals who plan to attend and require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Shawn Woodhead Werth, Commission Secretary and Clerk, at (202) 694–1040, at least 72 hours prior to the hearing date. PERSON TO CONTACT FOR INFORMATION: Judith Ingram, Press Officer. Telephone: (202) 694–1220. DATE AND TIME: Shawn Woodhead Werth, Secretary and Clerk of the Commission. [FR Doc. 2011–20031 Filed 8–3–11; 4:15 pm] BILLING CODE 6715–01–P FEDERAL RESERVE SYSTEM erowe on DSKG8SOYB1PROD with NOTICES Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. VerDate Mar<15>2010 15:16 Aug 04, 2011 Jkt 223001 Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than August 19, 2011. A. Federal Reserve Bank of Richmond (Adam M. Drimer, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528: 1. James S. MacLeod, Hilton Head Island, South Carolina; to acquire up to 31.36 percent of the voting shares of CoastalSouth Bancshares, Inc., Hilton Head Island, South Carolina, and thereby acquire shares of CoastalStates Bank, Hilton Head, South Carolina. Board of Governors of the Federal Reserve System, August 2, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–19894 Filed 8–4–11; 8:45 am] A. Federal Reserve Bank of Dallas (E. Ann Worthy, Vice President) 2200 North Pearl Street, Dallas, Texas 75201– 2272: 1. Adam Bank Group, Inc, Tampa, Florida, to acquire 100 percent of Brazos Valley Bank, National Association, College Station, Texas. Board of Governors of the Federal Reserve System, August 2, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–19893 Filed 8–4–11; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct ACTION: FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 1, 2011. Frm 00053 Fmt 4703 Office of the Secretary, HHS. Notice. AGENCY: BILLING CODE 6210–01–P PO 00000 47589 Sfmt 4703 Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Sheng Wang, PhD, Boston University School of Medicine Cancer Research Center: Based on the Respondent’s acceptance of ORI’s research misconduct findings, ORI found that Dr. Sheng Wang, who has been an Assistant Professor, Department of Medicine, Boston University School of Medicine Cancer Research Center (BUSM), engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA102940 and R01 CA101992. ORI found that the Respondent engaged in research misconduct by fabricating data that were included in two (2) published papers: SUMMARY: 1. Zhang, B., Faller, D.V., Wang, S. ‘‘HIC1 regulates tumor cell responses to endocrine therapies.’’ Mol. Endocrinol. 23(12):2075–85, 2009; and 2. Zhang, B., Chambers, K.J., Leprince, D., Faller, D.V., Wang, S. ‘‘Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.’’ Oncogene 28(5):651–61, 2009. Specifically, ORI found that Respondent: • Fabricated RT–PCR and ChIP experiments represented in Figures 1b, 2b, 3a,b, 4b,c, 6a,b, 7c in Mol. Endocrinol. 23(12):2075–85, 2009; RT– PCR and/or ChIP experiments were included in six (6) of seven (7) figures in this publication; and • Fabricated RT–PCR and ChIP experiments represented in Figures 2a,b, E:\FR\FM\05AUN1.SGM 05AUN1 47590 Federal Register / Vol. 76, No. 151 / Friday, August 5, 2011 / Notices 3a,b, 4a,c, 5a,b, 6b,c, 8a,b in Oncogene 28(5):651–61, 2009; RT–PCR and/or ChIP experiments were included in six (6) of eight (8) figures in this publication. Respondent has entered into a Voluntary Exclusion Agreement (Agreement). Respondent and the U.S. Public Health Service (PHS) want to conclude this matter without further expenditure of time or other resources. Respondent accepts ORI’s findings of research misconduct as set forth above but neither admits nor denies committing research misconduct. The Agreement does not constitute an admission of liability on Respondent’s part. Respondent agrees not to appeal the jurisdiction of ORI or request a U.S. Department of Health and Human Services (HHS) administrative hearing to review the findings as set forth in the Agreement. As a condition of the Agreement, Respondent agrees that the Mol. Endocrinol. 23(12):2075–85, 2009, and Oncogene 28(5):651–61, 2009, publications be retracted. In entering into the Agreement, Dr. Wang has voluntarily agreed for a period of two (2) years, beginning on July 18, 2011: (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); and (2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: erowe on DSKG8SOYB1PROD with NOTICES Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–19930 Filed 8–4–11; 8:45 am] BILLING CODE 4150–31–P VerDate Mar<15>2010 15:16 Aug 04, 2011 Jkt 223001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women (ACBCYW) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee: Times and Dates 9 a.m.–5 p.m., September 21, 2011. 8 a.m.–4:30 p.m., September 22, 2011. 8 a.m.–2:30 p.m., September 23, 2011. Place: CDC, Building 19, Auditorium B, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Atlanta, Georgia 30333. Status: Open to the public, limited only by the space available. Purpose: The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials. Matters to Be Discussed: The agenda will include discussions on health communications tools and resources related to breast cancer in young women including appropriate venues to educate women at increased risk for developing breast cancer at younger ages; and approaches to increase awareness of clinicians/practitioners regarding topics such as breast health, symptoms, diagnosis, and treatment of breast cancer in young women. Agenda items are subject to change as priorities dictate. Online Registration Required: In order to expedite the security clearance process required for entry into a Federal building, all ACBCYW attendees must register for the meeting online at least 21 days in advance at https://www.cdc.gov/cancer/breast/ what_cdc_is_doing/meetings.htm. Please complete all the required fields before submitting your registration and submit no later than August 29, 2011. Each meeting day, attendees must provide CDC staff and security with a driver’s license/state issued identification, or passport. Contact Person for More Information: Temeika L. Fairley, PhD, Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 5770 Buford Highway, NE., Mailstop K52, Atlanta, Georgia 30341, Telephone: (770) 488–4518, Fax: (770) 488–4760. The Director, Management Analysis and Services Office, has been delegated the PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and Agency for Toxic Substances and Disease Registry. Dated: July 29, 2011. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2011–19869 Filed 8–4–11; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee: Board Public Meeting Times and Dates (All times are Pacific Time): 8:15 a.m.–5 p.m., August 23, 2011. 8:15 a.m.–4:45 p.m., August 24, 2011. 8:15 a.m.–12:30 p.m., August 25, 2011. Public Comment Times and Dates (All times are Pacific Time): 5 p.m.–6 p.m.*, August 23, 2011. 5 p.m.–6:30 p.m.*, August 24, 2011. *Please note that the public comment periods may end before the times indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend public comment sessions at the start times listed. Place: Courtyard by Marriott, 480 Columbia Point, Richland, Washington 99352, Telephone: (509) 942–9400, Fax: (509) 942–9401. Audio Conference Call via FTS Conferencing. The USA toll-free, dial-in number is 1–866–659–0537 with a pass code of 9933701. Status: Open to the public, limited only by the space available. The meeting space accommodates approximately 150 people. Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of E:\FR\FM\05AUN1.SGM 05AUN1

Agencies

[Federal Register Volume 76, Number 151 (Friday, August 5, 2011)]
[Notices]
[Pages 47589-47590]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19930]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Sheng Wang, PhD, Boston University School of Medicine Cancer 
Research Center: Based on the Respondent's acceptance of ORI's research 
misconduct findings, ORI found that Dr. Sheng Wang, who has been an 
Assistant Professor, Department of Medicine, Boston University School 
of Medicine Cancer Research Center (BUSM), engaged in research 
misconduct in research supported by National Cancer Institute (NCI), 
National Institutes of Health (NIH), grants R01 CA102940 and R01 
CA101992.
    ORI found that the Respondent engaged in research misconduct by 
fabricating data that were included in two (2) published papers:

    1. Zhang, B., Faller, D.V., Wang, S. ``HIC1 regulates tumor cell 
responses to endocrine therapies.'' Mol. Endocrinol. 23(12):2075-85, 
2009; and
    2. Zhang, B., Chambers, K.J., Leprince, D., Faller, D.V., Wang, 
S. ``Requirement for chromatin-remodeling complex in novel tumor 
suppressor HIC1-mediated transcriptional repression and growth 
control.'' Oncogene 28(5):651-61, 2009.

    Specifically, ORI found that Respondent:
     Fabricated RT-PCR and ChIP experiments represented in 
Figures 1b, 2b, 3a,b, 4b,c, 6a,b, 7c in Mol. Endocrinol. 23(12):2075-
85, 2009; RT-PCR and/or ChIP experiments were included in six (6) of 
seven (7) figures in this publication; and
     Fabricated RT-PCR and ChIP experiments represented in 
Figures 2a,b,

[[Page 47590]]

3a,b, 4a,c, 5a,b, 6b,c, 8a,b in Oncogene 28(5):651-61, 2009; RT-PCR 
and/or ChIP experiments were included in six (6) of eight (8) figures 
in this publication.
    Respondent has entered into a Voluntary Exclusion Agreement 
(Agreement). Respondent and the U.S. Public Health Service (PHS) want 
to conclude this matter without further expenditure of time or other 
resources. Respondent accepts ORI's findings of research misconduct as 
set forth above but neither admits nor denies committing research 
misconduct. The Agreement does not constitute an admission of liability 
on Respondent's part. Respondent agrees not to appeal the jurisdiction 
of ORI or request a U.S. Department of Health and Human Services (HHS) 
administrative hearing to review the findings as set forth in the 
Agreement.
    As a condition of the Agreement, Respondent agrees that the Mol. 
Endocrinol. 23(12):2075-85, 2009, and Oncogene 28(5):651-61, 2009, 
publications be retracted.
    In entering into the Agreement, Dr. Wang has voluntarily agreed for 
a period of two (2) years, beginning on July 18, 2011:
    (1) To exclude himself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide 
Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment 
Regulations''); and
    (2) To exclude himself from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2011-19930 Filed 8-4-11; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.